TY - JOUR
T1 - Disodium cromoglycate, a new compound for the prevention of exacerbations of asthma
AU - Chen, Joyce L.
AU - Moore, Nicholas
AU - Norman, Philip S.
AU - Van Metre, Thomas E.
N1 - Funding Information:
From the Division of Allergy and Infectious Diseases, Department of Medicine, The Johns Hopkins University and Hospital. Supported by Training Grant AI-0009 of the National Institute of Allergy and Infectious Diseases and a grant by Fisons Pharmaceutical, Ltd. Received for publication July 31, 1968. *Recipient of a Research Career Development Award from the National Institutes of Allergy and Infectious Diseases.
PY - 1969/2
Y1 - 1969/2
N2 - Disodium cromoglycate (Intal, FPL 670) has been found to inhibit the broncho-spastic response to inhaled antigens in asthmatic patients. Its efficacy in the treatment of bronchial asthma was studied by a double-blind crossover method in 22 patients with persistent, perennial asthma. Each patient received either 2 weeks of disodium cromoglycate, by inhalation 4 times a day, followed by 2 weeks of placebo or the reverse. Daily diaries of symptoms and medication use were kept by each patient so that scores could be calculated from these diaries. Weekly physical examinations, FEV1, sputum cultures, blood chemistries, liver function tests, and urinalyses were obtained. Accumulated scores showed that 15 out of 22 patients improved on disodium cromoglycate. Two of the 15 patients had dramatic improvement whereas 13 patients had variable degrees of mild improvement. Analysis of variance showed that the difference between the treated and placebo periods was significant at the 2 per cent level. No untoward side effects were noted.
AB - Disodium cromoglycate (Intal, FPL 670) has been found to inhibit the broncho-spastic response to inhaled antigens in asthmatic patients. Its efficacy in the treatment of bronchial asthma was studied by a double-blind crossover method in 22 patients with persistent, perennial asthma. Each patient received either 2 weeks of disodium cromoglycate, by inhalation 4 times a day, followed by 2 weeks of placebo or the reverse. Daily diaries of symptoms and medication use were kept by each patient so that scores could be calculated from these diaries. Weekly physical examinations, FEV1, sputum cultures, blood chemistries, liver function tests, and urinalyses were obtained. Accumulated scores showed that 15 out of 22 patients improved on disodium cromoglycate. Two of the 15 patients had dramatic improvement whereas 13 patients had variable degrees of mild improvement. Analysis of variance showed that the difference between the treated and placebo periods was significant at the 2 per cent level. No untoward side effects were noted.
UR - http://www.scopus.com/inward/record.url?scp=0014466111&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0014466111&partnerID=8YFLogxK
U2 - 10.1016/0021-8707(69)90129-4
DO - 10.1016/0021-8707(69)90129-4
M3 - Article
C2 - 4178832
AN - SCOPUS:0014466111
SN - 0021-8707
VL - 43
SP - 89
EP - 100
JO - Journal of Allergy
JF - Journal of Allergy
IS - 2
ER -